Gapping up
In reaction to strong earnings/guidance:
- MX +24.6%, BTI +0.8%, WPP +0.8% (reaffirms guidance)
M&A news:
- MAT +4.5% (reports the company received/rejected another MGA Entertainment bid)
Other news:
- SYBX +20.4% (Synlogic and Ginkgo Bioworks announce platform collaboration -- agreement provides an $80 mln equity investment at a premium in Synlogic by Ginkgo and entry into a long-term strategic platform collaboration)
- TSLA +3.9% (following annual meeting)
- AAT +3.7% (prices offering of 9.5 mln shares of common stock at $44.75 per share)
- IMV +3.5% (updated data from ongoing investigator-sponsored SPiReL Phase 2 clinical trial)
- SMAR +1.2% (prices upsized underwritten public offering of its Class A common stock at a price to the public of $43.50 per share)
- PETX +0.8% (granted FDA approval of NOCITA 10 mL vial; Commercial availability anticipated by fall 2019)
- CTRN +0.5% (announces resignation of CEO Bruce Smith)
Analyst comments:
- CBAY +8.3% (upgraded to Strong Buy at Raymond James)
- EAT +3.8% (upgraded to Outperform at Telsey Advisory Group)
- COMM +2.8% (upgraded to Buy from Neutral at Rosenblatt)
- FTCH +2.6% (initiated with an Overweight at KeyBanc Capital Markets)
- JNPR +0.8% (upgraded to Neutral from Sell at Rosenblatt)